688105.SH
诺唯赞
SSE · Healthcare · Biotechnology · CN
CNY 22.51
−7.14%Year over year
Reported trailing growth
- Revenue
- +3.8%
- EBITDA
- —
- EBIT
- +29.5%
- EPS
- +49.7%
- Free cash flow
- +500.7%
- Operating cash flow
- +1148.2%
Forward estimates
Based on analyst estimates
- Revenue
- +103.5%
- EBITDA
- +50.0%
- EPS
- -40.6%
Three-year CAGR
- Revenue
- -27.2%
- EBITDA
- -48.2%
- EBIT
- +35.5%
- Net income
- +8.2%
- EPS
- +20.0%
- Free cash flow
- +319.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026